Remo Panaccione (R Panaccione)

ORCID

Publication Activity (10 Years)

Years Active: 2019-2024
Publications (10 Years): 44

Top Venues

Alimentary pharmacology & therapeutics

Inflammatory bowel diseases

Journal of Crohn's & colitis

Crohn's & colitis 360

University of Calgary

This page only lists publications with an associated author ORCID identifier.

Affiliation History

University of Calgary Jul 01 1999

Canada

Director, Inflammatory Bowel disease Unit, Professor of Medicine :: Medicine

Publications

Bruce E Sands, Geert R A M D'Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory bowel diseases (2024)
Remo Panaccione
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply. Alimentary pharmacology & therapeutics 59 (4) (2024)
Corey Allan Siegel, Victoria Rai, An Outtier, Severine Vermeire, Cindy C W Law, Bruce E Sands, Asim Abdulhamid, Richard Gearry, Josh McGuire, James O Lindsay, Remo Panaccione, Hagai Schweistein, Iris Dotan, Luca Scarallo, Anne M Griffiths, Marla C Dubinsky, null null
Recommendations for Broadening Eligibility Criteria in Inflammatory Bowel Disease Clinical Trials. Journal of Crohn's & colitis (2024)
Kenneth Ernest-Suarez, Luis E Murguía-Favela, Kerri L Novak, Remo Panaccione, Cora Constantinescu, Cynthia H-T Seow
Normal Infant Immunologic Assessment and Uneventful Live Rotavirus Vaccination Despite Continuous Tofacitinib Exposure In Utero and During Breastfeeding. Crohn's & colitis 360 6 (1) (2024)
Catherine Rowan, Fiona Yeaman, Kenneth Ernest-Suarez, Marie-Louise Martin, Remo Panaccione, Tushar Shukla, Matt Grossi, Meghan Vlasschaert, Kerri L Novak, Cynthia H-T Seow
Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy. Inflammatory bowel diseases 30 (5) (2024)
Bruce E Sands, Geert R A M D'Haens, David B Clemow, Peter M Irving, Jordan T Johns, Theresa Hunter Gibble, Maria T Abreu, Scott Lee, Tadakazu Hisamatsu, Taku Kobayashi, Marla C Dubinsky, Severine Vermeire, Corey A Siegel, Laurent Peyrin-Biroulet, Richard E Moses, Joe Milata, Vipin Arora, Remo Panaccione, Axel Dignass
Two-Year Efficacy and Safety of Mirikizumab Following 104 Weeks of Continuous Treatment for Ulcerative Colitis: Results From the LUCENT-3 Open-Label Extension Study. Inflammatory bowel diseases (2024)
Remo Panaccione, Christopher Ma, Vipul Jairath, Axel Dignass, Namita Joshi, Ryan Clark, Jenny Griffith, Kristina Kligys, Monika Semwal, Zachary Smith, Dominic Mitchell, Dominic Nunag, Marc Ferrante
Achievement of Endoscopic Remission After Induction Reduces Hospitalization Burden in Crohn's Disease: Findings From a Pooled Post Hoc Analysis of Risankizumab and Upadacitinib Phase III Trials. Journal of Crohn's & colitis (2024)
Catherine Rowan, Fiona Yeaman, Kenneth Ernest-Suarez, Marie-Louise Martin, Remo Panaccione, Tushar Shukla, Matt Grossi, Meghan Vlasschaert, Kerri L Novak, Cynthia H-T Seow
Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy. Inflammatory bowel diseases 30 (5) (2024)
Catherine Rowan, Fiona Yeaman, Kenneth Ernest-Suarez, Marie-Louise Martin, Remo Panaccione, Tushar Shukla, Matt Grossi, Meghan Vlasschaert, Kerri L Novak, Cynthia H-T Seow
Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy. Inflammatory bowel diseases 30 (5) (2024)
Vipul Jairath, Waqqas Afif, Brian Bressler, Janet E Pope, Daniel Selchen, Joseph W Windsor, Remo Panaccione
Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies. Journal of the Canadian Association of Gastroenterology 7 (4) (2024)
Remo Panaccione
Editorial: Extending upadacitinib induction dosing in ulcerative colitis-A delicate balance of efficacy and safety. Author's reply. Alimentary pharmacology & therapeutics 59 (4) (2024)
Catherine Rowan, Fiona Yeaman, Kenneth Ernest-Suarez, Marie-Louise Martin, Remo Panaccione, Tushar Shukla, Matt Grossi, Meghan Vlasschaert, Kerri L Novak, Cynthia H-T Seow
Tofacitinib as a Rescue Therapy for Ulcerative Colitis in Pregnancy. Inflammatory bowel diseases (2024)
Reena Khanna, Brian G Feagan, Guangyong Zou, Larry W Stitt, John W D McDonald, Brian Bressler, Remo Panaccione, Lisa M Shackelton, Tanja VanViegen, Edward V Loftus, Marco Daperno, Vipul Jairath, Geert R A M D'Haens, William J Sandborn
Reliability and Responsiveness of Clinical and Endoscopic Outcome Measures in Crohn's Disease. Inflammatory bowel diseases (2024)
Vipul Jairath, Waqqas Afif, Brian Bressler, Janet E Pope, Daniel Selchen, Joseph W Windsor, Remo Panaccione
Practical guidance for managing patients with moderate-to-severe ulcerative colitis using small molecule therapies. Journal of the Canadian Association of Gastroenterology 7 (4) (2024)
Charles N Bernstein, Remo Panaccione, Zoann Nugent, Deborah A Marshall, Gilaad G Kaplan, Stephen Vanner, Levinus A Dieleman, Lesley A Graff, Anthony Otley, Jennifer Jones, Michelle Buresi, Sanjay Murthy, Mark Borgaonkar, Brian Bressler, Alain Bitton, Kenneth Croitoru, Sacha Sidani, Aida Fernandes, Paul Moayyedi
Crohn's Disease Phenotypes and Associations With Comorbidities, Surgery Risk, Medications and Nonmedication Approaches: The MAGIC in IMAGINE Study. Inflammatory bowel diseases (2024)
Christopher Ma, Brian G Feagan, Zhongya Wang, Guangyong Zou, Michelle I Smith, Lisa M Shackelton, Bruce E Sands, Remo Panaccione, Geert R D'Haens, Séverine Vermeire, Vipul Jairath
Re-evaluating Methods for Assessing Differences in Response in Ileal vs. Colonic Crohn's Disease: A Post-hoc Analysis of the FITZROY Trial. Journal of Crohn's & colitis (2024)
Kenneth Ernest-Suarez, Luis E Murguía-Favela, Kerri L Novak, Remo Panaccione, Cora Constantinescu, Cynthia H-T Seow
Normal Infant Immunologic Assessment and Uneventful Live Rotavirus Vaccination Despite Continuous Tofacitinib Exposure In Utero and During Breastfeeding. Crohn's & colitis 360 6 (1) (2024)
Stefan Schreiber, Raymond K Cross, Remo Panaccione, Geert D'Haens, Peter Bossuyt, Iris Dotan, Jean Frederic Colombel, Edouard Louis, Marla C Dubinsky, Kristina Kligys, Ezequiel Neimark, Alexandra Song, Javier Zambrano, Jasmina Kalabic, Erica Cheng, Yafei Zhang, Marc Ferrante
Efficacy and safety of risankizumab by baseline corticosteroid use and achievement of corticosteroid-free clinical and endoscopic outcomes in patients with moderately to severely active Crohn's disease. Alimentary pharmacology & therapeutics (2024)
Marc Ferrante, Peter M Irving, Maria T Abreu, Jeffrey Axler, Xiang Gao, Qian Cao, Toshimitsu Fujii, Astrid Rausch, Joanna Torres, Ezequiel Neimark, Alexandra Song, Kori Wallace, Kristina Kligys, Sofie Berg, Xiaomei Liao, Qing Zhou, Jasmina Kalabic, Brian Feagan, Remo Panaccione
Maintenance Risankizumab Sustains Induction Response in Patients with Crohn's Disease in a Randomized Phase 3 Trial. Journal of Crohn's & colitis (2023)
Patrick Hamilton, Katherine Buhler, John K MacDonald, Gilaad G Kaplan, Cynthia H-T Seow, Cathy Lu, Kerri L Novak, Christopher N Andrews, Siddharth Singh, Vipul Jairath, Remo Panaccione, Christopher Ma
Meta-analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm. Alimentary pharmacology & therapeutics 57 (8) (2023)
Sangmin Lee, Cynthia H Seow, Kara Nerenberg, Stefania Bertazzon, Yvette Leung, Vivian Wai-Mei Huang, Tara Whitten, Stephanie Coward, Remo Panaccione, Gilaad G Kaplan, Amy Metcalfe
Despite Increased Disease Activity, Women who Attended a Dedicated Inflammatory Bowel Disease and Pregnancy Clinic Had Infants With Higher Apgar Scores: A Population-Based Study. Inflammatory bowel diseases (2023)
Jean-Frederic Colombel, Stefan Schreiber, Geert D'Haens, Joanne Rizzo, Kristina Kligys, Jenny Griffith, Javier Zambrano, Qian Zhou, Yafei Zhang, Jasmina Kalabic, Florian Rieder, Marla Dubinsky, Remo Panaccione
Risankizumab Induction Therapy Achieves Early Symptom Improvements That Are Associated With Future Clinical and Endoscopic Outcomes in Crohn's Disease: Post Hoc Analysis of the ADVANCE, MOTIVATE, and FORTIFY Phase 3 Studies. Journal of Crohn's & colitis (2023)
Patrick Hamilton, Katherine Buhler, John K MacDonald, Gilaad G Kaplan, Cynthia H-T Seow, Cathy Lu, Kerri L Novak, Christopher N Andrews, Siddharth Singh, Vipul Jairath, Remo Panaccione, Christopher Ma
Meta-analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm. Alimentary pharmacology & therapeutics (2023)
Harris A Ahmad, James E East, Remo Panaccione, Simon P L Travis, James B Canavan, Keith Usiskin, Michael F Byrne
Artificial Intelligence in Inflammatory Bowel Disease Endoscopy: Implications for Clinical Trials. Journal of Crohn's & colitis (2023)
Simon P L Travis, Alison Potts Bleakman, Marla C Dubinsky, Stefan Schreiber, Remo Panaccione, Toshifumi Hibi, Theresa Hunter Gibble, Cem Kayhan, Christian Atkinson, Christophe Sapin, Eoin J Flynn, David T Rubin
The Communicating Needs and Features of IBD Experiences (CONFIDE) Study: US and European Patient and Health Care Professional Perceptions of the Experience and Impact of Symptoms of Moderate-to-Severe Ulcerative Colitis. Inflammatory bowel diseases (2023)
Silvio Danese, Remo Panaccione, Maria T Abreu, David T Rubin, Subrata Ghosh, Axel Dignass, Anita Afzali, Douglas C Wolf, Michael V Chiorean, Severine Vermeire, Anjali Jain, Lorna Charles, Garrett Lawlor, Mark T Osterman, Hsiuanlin Wu, James B Canavan, Ann Katrin Petersen, Jean Frederic Colombel, Miguel Regueiro
Efficacy and safety of approximately 3 years of continuous ozanimod in moderately to severely active ulcerative colitis: interim analysis of the True North open-label extension. Journal of Crohn's & colitis (2023)
Florence-Damilola Odufalu, Marla C Dubinsky, Laurent Peyrin-Biroulet, Karoliina Ylänne, Allyson Sipes, Joseph C Cappelleri, Leo J Russo, Michelle Segovia, Sean Gardiner, Edward P Johnson, Amy Mulvey, Remo Panaccione
Health Care Disparities, Social Determinants of Health, and Emotional Impacts in Patients with Ulcerative Colitis: Results from a Global Ulcerative Colitis Narrative Patient Survey. Inflammatory bowel diseases (2023)
Patrick Hamilton, Katherine Buhler, John K MacDonald, Gilaad G Kaplan, Cynthia H-T Seow, Cathy Lu, Kerri L Novak, Christopher N Andrews, Siddharth Singh, Vipul Jairath, Remo Panaccione, Christopher Ma
Meta-analysis: Placebo rates in microscopic colitis randomised trials and applications for future drug development using a historical control arm. Alimentary pharmacology & therapeutics 57 (8) (2023)
Remo Panaccione, Eric B Collins, Gil Y Melmed, Severine Vermeire, Silvio Danese, Peter D R Higgins, Christina S Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohn's & colitis 360 5 (2) (2023)
Kenneth Ernest-Suarez, Remo Panaccione
Update on the role of upadacitinib in the treatment of adults with moderately to severely active ulcerative colitis. Therapeutic advances in gastroenterology 16 (2023)
Remo Panaccione, Silvio Danese, Wen Zhou, Justin Klaff, Dapo Ilo, Xuan Yao, Gweneth Levy, Peter D R Higgins, Edward V Loftus, Su Chen, Yuri Sanchez Gonzalez, Carolyn Leonard, Xavier Hébuterne, James O Lindsay, Qian Cao, Hiroshi Nakase, Jean Frederic Colombel, Séverine Vermeire
Efficacy and safety of upadacitinib for 16-week extended induction and 52-week maintenance therapy in patients with moderately to severely active ulcerative colitis. Alimentary pharmacology & therapeutics (2023)
Bram Verstockt, Severine Vermeire, Laurent Peyrin-Biroulet, Rebecca A Mosig, Brian G Feagan, Jean-Frederic Colombel, Britta Siegmund, Florian Rieder, Stefan Schreiber, Andres Yarur, Remo Panaccione, Marla Dubinsky, Simon Lichtiger, Fabio Cataldi, Silvio Danese
The Safety, Tolerability, Pharmacokinetics and Clinical Efficacy of the NLRX1 agonist NX-13 in Active Ulcerative Colitis: Results of a Phase 1b Study. Journal of Crohn's & colitis (2023)
Jared Cooper, Ante Markovinovic, Stephanie Coward, Michelle Herauf, Abdel-Aziz Shaheen, Mark Swain, Remo Panaccione, Christopher Ma, Cathy Lu, Kerri Novak, Karen I Kroeker, Siew C Ng, Gilaad G Kaplan
Incidence and Prevalence of Primary Sclerosing Cholangitis: A Meta-analysis of Population-based Studies. Inflammatory bowel diseases (2023)
Remo Panaccione, Eric B Collins, Gil Y Melmed, Severine Vermeire, Silvio Danese, Peter D R Higgins, Christina S Kwon, Wen Zhou, Dapo Ilo, Dolly Sharma, Yuri Sanchez Gonzalez, Si-Tien Wang
Efficacy and Safety of Advanced Therapies for Moderately to Severely Active Ulcerative Colitis at Induction and Maintenance: An Indirect Treatment Comparison Using Bayesian Network Meta-analysis. Crohn's & colitis 360 5 (2) (2023)
Michael Klonarakis, Christopher N Andrews, Maitreyi Raman, Remo Panaccione, Christopher Ma
Review article: therapeutic targets for the pharmacologic management of coeliac disease-the future beyond a gluten-free diet. Alimentary pharmacology & therapeutics 55 (10) (2022)
Remo Panaccione, Maria T Abreu, Irina Lazariciu, Rajiv Mundayat, Nervin Lawendy, Leonardo Salese, John C Woolcott, Bruce E Sands, Maria Chaparro
Persistence of treatment in patients with ulcerative colitis who responded to tofacitinib therapy: data from the open-label, long-term extension study, OCTAVE open. Alimentary pharmacology & therapeutics 55 (12) (2022)
Remo Panaccione, John D Isaacs, Lea Ann Chen, Wenjin Wang, Amy Marren, Kenneth Kwok, Lisy Wang, Gary Chan, Chinyu Su
Correction to: Characterization of Creatine Kinase Levels in Tofacitinib‑Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive diseases and sciences (2020)
Edward V Loftus, Brian G Feagan, Remo Panaccione, Jean Frederic Colombel, William J Sandborn, Bruce E Sands, Silvio Danese, Geert R A M D'Haens, David T Rubin, Ira Shafran, Andrejus Parfionovas, Raquel Rogers, Richard A Lirio, Severine Vermeire
Long-term safety of vedolizumab for inflammatory bowel disease. Alimentary pharmacology & therapeutics 52 (8) (2020)
Remo Panaccione, John D Isaacs, Lea Ann Chen, Wenjin Wang, Amy Marren, Kenneth Kwok, Lisy Wang, Gary Chan, Chinyu Su
Characterization of Creatine Kinase Levels in Tofacitinib-Treated Patients with Ulcerative Colitis: Results from Clinical Trials. Digestive diseases and sciences 66 (8) (2020)
Christopher Ma, Siddharth Singh, Joan Heatherington, Remo Panaccione
Editorial: is age just a number when it comes to treatment of inflammatory bowel disease? Alimentary pharmacology & therapeutics 52 (10) (2020)
Remo Panaccione, Silvio Danese, William J Sandborn, Christopher D O'Brien, Yiying Zhou, Hongyan Zhang, Omoniyi J Adedokun, Ilia Tikhonov, Stephan Targan, Maria T Abreu, Tadakazu Hisamatsu, Ellen J Scherl, Rupert W Leong, David S Rowbotham, Ramesh Pulendran Arasaradnam, Bruce E Sands, Colleen Marano
Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy. Alimentary pharmacology & therapeutics 52 (11-12) (2020)
Christopher Ma, Jeffrey K Lee, Anish R Mitra, Anouar Teriaky, Daksh Choudhary, Tran M Nguyen, Niels Vande Casteele, Reena Khanna, Remo Panaccione, Brian G Feagan, Vipul Jairath
Systematic review with meta-analysis: efficacy and safety of oral Janus kinase inhibitors for inflammatory bowel disease. Alimentary pharmacology & therapeutics 50 (1) (2019)
Christopher Ma, A Almutairdi, D Tanyingoh, Cynthia H-T Seow, Kerri L Novak, C Lu, Remo Panaccione, Gilaad G Kaplan, Paulo Gustavo Kotze
Reduction in surgical stoma rates in Crohn's disease: a population-based time trend analysis. Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland 21 (11) (2019)
Geert R A M D'Haens, James O Lindsay, Remo Panaccione, Stefan Schreiber
Ulcerative Colitis: Shifting Sands. Drugs in R&D 19 (2) (2019)

Remo Panaccione (R Panaccione)

Publication Activity (10 Years)

Top Topics

Top Venues